MESH search terms were 'calcium', 'calcium compounds' and 'blood pressure' or 'hypertension', combined with keyword searches of 'randomised controlled trials' and 'meta-analysis' and a text search for the word 'randomised'. EMBASE was searched for the same period using the terms 'calcium carbonate', 'calcium citrate', 'calcium gluconate', or 'calcium and diet' and 'blood pressure' or 'hypertension'. The bibliographies of included studies were searched to identify further relevant studies. Key researchers in the field were contacted to identify additional unpublished data sources. Authors of articles with insufficient data for abstraction were contacted.
Specific interventions included in the review
Calcium supplementation at a level of greater than 1000mg per day, either as a non-dietary intervention in the form of calcium gluconate, calcium carbonate, calcium citrate, calcium citrate malate, or as a dietary supplementation either as a milk/dairy product supplement or through other dietary manipulation.
Participants included in the review
Non-pregnant normotensive or hypertensive patients.
Outcomes assessed in the review
Systolic and diastolic blood pressure.
How were decisions on the relevance of primary studies made?
Two reviewers independently assessed all articles for retrieval. All articles identified as potentially relevant by either reviewer were retrieved.
Assessment of study quality
A methodological quality score was based on the major sources of potential bias and error in the studies. Studies were assessed on the following: concealment of random allocation; blinding of participants, caregivers, and blood pressure measurements; formal training of blood pressure measurers and specification of measurement techniques. Two reviewers independently assessed the validity of each included study.
Data extraction
Two reviewers independently extracted all data, disagreements were resolved by consensus. 
Methods of synthesis
How were the studies combined?
A random-effects model was used to combine data from continuous outcome variables. The approach by Fleiss (see Other Publications of Related Interest) was used to account for differences in treatment effects between studies.
How were differences between studies investigated?
A chi-squared test for heterogeneity was conducted and potential sources of heterogeneity were investigated. Possible sources investigated included: age and sex of subjects, normotensive versus hypertensive participants, baseline calcium, dietary versus non-dietary calcium supplementation, and the methodological quality of the studies.
Results of the review
Forty-two randomised controlled trials, 10 of these studies were not included in the earlier review. 10 of the 42 studies presented data in a way which permitted calculation of summary statistics, and 23 of the remaining 31 studies provided additional data that allowed pooling of results. A total of 4560 participants were included in the review, 2068 randomised to calcium supplementation, 2059 receiving no calcium or placebo, and 433 involving cross-over trials in which they received both calcium and placebo.
The pooled analysis of all studies showed a reduction in systolic blood pressure of -1.44mm Hg (95% CI: -2.20, -0.68, p<0.001) and a reduction in diastolic blood pressure of -0.84 mm Hg (95% CI: -1.44, -0.24, p<0.001). For both estimates of treatment effect evidence of heterogeneity was found at the 5% level. Investigation into the possible sources of heterogeneity showed only significant differences at the 5% level in trials that reported subgroups of hypertensive versus normotensive patients. The summary treatment effect estimates for dietary (n=9 trials) compared to non-dietary (n=33) sources of calcium supplementation showed no evidence for a difference in systolic (p=0.14) and diastolic (p=0.67) blood pressure. There was no evidence of heterogeneity in the dietary trials, but statistically significant heterogeneity at the 5% level remained in the non-dietary trials.
